Figure 4.The inhibitory effects of pharmacological inhibition of USP8 in HCC in vivo. (A) USP8i significantly inhibits HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg or 1 mg/kg once per day, intraperitoneal injection). (B) Combination of USP8i and doxorubicin is superior than in inhibiting HepG2 growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection), doxorubicin (4 mg/kg once per five days, intraperitoneal injection,), or a combination of doxorubicin and USP8i. (C) USP8i significantly inhibited doxorubicin-resistant HepG2-r growth in mice. Mice were treated with vehicle alone, USP8i (0.5 mg/kg once per day, intraperitoneal injection). *p<0.01, compared to control or doxorubicin.
